Featured Research

from universities, journals, and other organizations

Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents

Date:
May 2, 2008
Source:
University of California - Los Angeles
Summary:
Low-dose antidepressant therapy can significantly improve the overall quality of life for adolescents suffering from irritable bowel syndrome, or IBS. The study is the first of its kind to look at the effects of amitriptyline, a tricyclic antidepressant, in the pediatric IBS population.

Researchers at Mattel Children's Hospital UCLA have found that low-dose antidepressant therapy can significantly improve the overall quality of life for adolescents suffering from irritable bowel syndrome, or IBS. The syndrome affects 6 percent of middle school students and 14 percent of high school kids in the United States.

Related Articles


The study, published in the May issue of the peer-reviewed Journal of Pediatrics, is the first of its kind to look at the effects of amitriptyline, a tricyclic antidepressant, in the pediatric IBS population, researchers said.

The research was conducted between 2002 and 2005 and involved 33 newly diagnosed IBS patients, including 24 girls, between the ages of 12 and 18.

Irritable bowel syndrome causes discomfort in the abdomen, along with diarrhea, constipation or both. Currently, there is no cure, and treatments only lessen the symptoms.

"While research has shown that amitriptyline is effective for adults with IBS, only peppermint oil has been studied in children with this disorder in a double-blind, placebo-controlled fashion," said Dr. Ron J. Bahar, assistant clinical professor of pediatric gastroenterology at Mattel Children's Hospital UCLA and lead author of the study. "Our results show that amitriptyline significantly improves overall quality-of-life measurements in adolescents and should be a therapeutic option for these patients. We were actually surprised to reach our conclusion with a relatively small number of subjects."

The 13-week study consisted of three phases: two weeks of enrollment and symptom scoring, eight weeks of therapy with amitriptyline or a placebo, and three weeks of post-medication "washout" and symptom scoring.

Patients were randomized in a double-blinded fashion to receive the antidepressant or a placebo and were surveyed at two, six, 10 and 13 weeks using a symptom checklist, a pain-rating scale, a pain intensity and frequency scale, and an IBS quality-of-life questionnaire.

The results showed that patients receiving amitriptyline were more likely to experience:

  • An improvement in overall quality of life at six, 10 and 13 weeks.
  • A reduction in IBS-associated diarrhea at six and 10 weeks.
  • A reduction in pain near the belly button at 10 weeks.
  • A reduction in pain in the right lower quadrant of the abdomen at six, 10 and 13 weeks.

Bahar said that more than half of eligible patients, or their parents or guardians, refused to enroll in the study because they were uncomfortable with using an antidepressant medication of any kind, citing negative reports in the media about their side effects and the Food and Drug Administration's formal 2004 "black box" warnings regarding the increased potential for suicide in children using antidepressants.

"However, the dose of AMI (amitriptyline) used in this study, as well as IBS treatment for adults, is far less than the dose to treat depression," Bahar said. "At these low levels, it could be considered a remedy to treat neuropathic pain associated with chronic pain symptoms, rather than an antidepressant or psychotropic medication."

The next stage of research will look at the long-term follow-up of these patients to determine who will continue to stay well on the medication, whose symptoms resolve spontaneously and what other medications can be used as an alternative to amitriptyline for adolescents with IBS.

The research was funded by James L. Brooks and the Diane Brooks Medical Research Foundation of the California Community Foundation, and by the pharmaceutical company AstraZeneca.

Other study authors included Dr. Brynie S. Collins, Dr. Barry Steinmetz and Dr. Marvin Ament.


Story Source:

The above story is based on materials provided by University of California - Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University of California - Los Angeles. "Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents." ScienceDaily. ScienceDaily, 2 May 2008. <www.sciencedaily.com/releases/2008/05/080501154222.htm>.
University of California - Los Angeles. (2008, May 2). Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2008/05/080501154222.htm
University of California - Los Angeles. "Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents." ScienceDaily. www.sciencedaily.com/releases/2008/05/080501154222.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins